Related Experiment Videos
Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy
1University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Abstract:
Monoclonal antibody (mAb) 225 against the human epidermal growth factor receptor blocks activation of receptor tyrosine kinase. This retards or arrests cell cycle progression, with accumulation of cells in G1 phase. The mechanism of growth inhibition involves increased levels of p27KIP1 and inhibition of cyclin-dependent kinase-2 activity. mAb in combination with chemotherapy exhibits a synergistic antitumor activity, with successful eradication of well-established tumor xenografts that resist treatment with either mAb or drug alone. A Phase I clinical trial has established the safety of repeated administration of human:mouse chimeric mAb 225 at concentrations that maintain receptor-saturating blood levels for up to 3 months. Phase I trials exploring mAb 225 treatment in combination with doxorubicin, cisplatin, or paclitaxel are ongoing.
Insights
Monoclonal antibody (mAb) 225 targeting the human epidermal growth factor receptor inhibits tumor growth by arresting the cell cycle. Combining this antibody with chemotherapy shows synergistic antitumor activity in preclinical models.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- The human epidermal growth factor receptor (EGFR) is a key target in cancer therapy.
- Monoclonal antibodies (mAbs) targeting EGFR have shown promise in cancer treatment.
- Understanding the mechanisms of mAb action and combination therapies is crucial.
Purpose of the Study:
- To investigate the anti-tumor effects of mAb 225 against EGFR.
- To elucidate the mechanism of growth inhibition induced by mAb 225.
- To evaluate the synergistic anti-tumor activity of mAb 225 in combination with chemotherapy.
Main Methods:
- Treatment of tumor xenografts with mAb 225 alone or in combination with chemotherapy agents.
- Cell cycle analysis to assess cell cycle progression and arrest.
- Western blot analysis to determine protein levels (e.g., p27KIP1) and enzyme activity (e.g., CDK2).
- Phase I clinical trials to assess safety and tolerability.
Main Results:
- mAb 225 blocks EGFR activation, leading to cell cycle arrest in the G1 phase.
- Inhibition of cyclin-dependent kinase-2 (CDK2) activity and increased p27KIP1 levels were observed.
- Combination therapy with mAb 225 and chemotherapy resulted in synergistic anti-tumor activity and eradication of resistant xenografts.
- Phase I trials demonstrated the safety of repeated administration of chimeric mAb 225.
Conclusions:
- mAb 225 is a potent inhibitor of EGFR signaling and exhibits anti-tumor activity.
- Combination of mAb 225 with chemotherapy offers a synergistic approach for cancer treatment.
- Chimeric mAb 225 is safe for repeated administration in humans, supporting further clinical investigation.